Literature DB >> 15645222

Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons.

Elise M Weerts1, Amy K Goodwin, Roland R Griffiths, P Rand Brown, Wolfgang Froestl, Cornelis Jakobs, K Michael Gibson.   

Abstract

RATIONALE: gamma-Hydroxybuyrate (GHB) is a current drug of abuse that may produce physical dependence.
OBJECTIVES: The present study characterized the behavioral effects of chronic GHB in baboons (n = 4), and evaluated whether signs of withdrawal occurred (1) after administration of the GABA-B antagonist CGP36742 during chronic GHB administration (precipitated withdrawal) and (2) following discontinuation of chronic GHB administration (spontaneous withdrawal).
METHODS: Water (vehicle) and then GHB was continuously infused via intragastric (IG) catheters. GHB administration was initiated at 350 mg/kg per day, and the dose was increased by 100 mg/kg over 4 days to 750 mg/kg per day. Food pellets were available 20 h/day under a fixed ratio (FR5 or 10) schedule of reinforcement. Observation sessions and a 2-min fine motor task were conducted during vehicle and GHB administration. CGP36742 (32 and 56 mg/kg, IM) was administered during vehicle and chronic GHB administration. After a total of 32-36 days GHB administration was abruptly discontinued. Blood samples were collected during all interventions and analyzed for GHB content.
RESULTS: Chronic GHB decreased food-maintained behavior, disrupted performance of the fine motor task, and produced ataxia, muscle relaxation, tremors and jerks. At the end of GHB administration, plasma levels of GHB ranged from 486 to 2080 micromol/L. Administration of CGP36742 during chronic GHB administration produced increases in aggression, self-directed behaviors, vomit/retch, tremors and/or jerks, which is consistent with a precipitated withdrawal syndrome. Similar signs were observed when GHB administration was discontinued. Seizures were not observed.
CONCLUSIONS: These data indicate that chronic GHB administration produced physical dependence and that activation of the GABA-B receptor may be important for GHB physical dependence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645222     DOI: 10.1007/s00213-004-2079-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients.

Authors:  G Addolorato; M Cibin; F Caputo; E Capristo; G L Gessa; G F Stefanini; G Gasbarrini
Journal:  Drug Alcohol Depend       Date:  1998-12-01       Impact factor: 4.492

2.  Maintaining abstinence from alcohol with gamma-hydroxybutyric acid.

Authors:  G Addolorato; M Cibin; E Capristo; F Beghe; G Gessa; G F Stefanini; G Gasbarrini; E Caprista
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

3.  The GABAB-receptor antagonist, CGP 35348, antagonises gamma-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice.

Authors:  H Nissbrandt; G Engberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid.

Authors:  M A Carai; G Colombo; G Brunetti; S Melis; S Serra; G Vacca; S Mastinu; A M Pistuddi; C Solinas; G Cignarella; G Minardi; G L Gessa
Journal:  Eur J Pharmacol       Date:  2001-10-12       Impact factor: 4.432

5.  Gamma hydroxybutyrate in the monkey. I. Electroencephalographic, behavioral, and pharmacokinetic studies.

Authors:  O C Snead
Journal:  Neurology       Date:  1978-07       Impact factor: 9.910

6.  The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons.

Authors:  Elise M Weerts; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

Review 7.  Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

Authors:  R R Griffiths; E M Weerts
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

8.  Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB.

Authors:  Yossef Itzhak; Syed F Ali
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 9.  From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid.

Authors:  C Guin Ting Wong; K Michael Gibson; O Carter Snead
Journal:  Trends Pharmacol Sci       Date:  2004-01       Impact factor: 14.819

Review 10.  Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.

Authors:  Michael McDonough; Noel Kennedy; Anthony Glasper; Jenny Bearn
Journal:  Drug Alcohol Depend       Date:  2004-07-15       Impact factor: 4.492

View more
  18 in total

1.  Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons.

Authors:  August F Holtyn; Elise M Weerts
Journal:  Exp Clin Psychopharmacol       Date:  2018-12-20       Impact factor: 3.157

Review 2.  Unravelling the brain targets of gamma-hydroxybutyric acid.

Authors:  Vincenzo Crunelli; Zsuzsa Emri; Nathalie Leresche
Journal:  Curr Opin Pharmacol       Date:  2005-12-20       Impact factor: 5.547

3.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

4.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

5.  Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.

Authors:  Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2010-08-21       Impact factor: 4.530

6.  Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.

Authors:  Amy K Goodwin; K Michael Gibson; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2013-03-26       Impact factor: 4.492

Review 7.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

8.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

9.  Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.

Authors:  Ina Knerr; K Michael Gibson; Cornelis Jakobs; Phillip L Pearl
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

10.  Gamma-hydroxybutyric acid in male and female cynomolgus monkeys trained to discriminate 1.0 or 2.0 g/kg ethanol.

Authors:  Christa M Helms; Laura S M Rogers; Kathleen A Grant
Journal:  Behav Pharmacol       Date:  2008-07       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.